The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)

Launched by FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI, MILANO · May 6, 2024

Keywords

ClinConnect Summary

The Epithelioid Hemangioendothelioma Registry is a clinical study aimed at learning more about a rare type of cancer called epithelioid hemangioendothelioma (EHE). This cancer is a form of soft tissue sarcoma, which means it starts in the connective tissues of the body. The study will collect information from patients who have recently been diagnosed with EHE, helping researchers understand how the disease behaves, find better treatments, and identify factors that may influence patient outcomes. The registry is being conducted in specialized centers across Europe and the UK, and patient recruitment started in December 2023.

To be eligible for this study, participants must be adults aged 18 or older and have a confirmed diagnosis of EHE by a specialist, including specific molecular tests that confirm the type of cancer. Once enrolled, patients will be monitored over time for any changes in their health, such as cancer progression or recurrence. This research is important because it aims to fill the gaps in knowledge about EHE, providing hope for better management and treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • New patients managed by the contributing centers with a pathological EHE diagnosis performed or verified by an expert sarcoma pathologist starting from 1 December 2023 onwards and to be performed within 6 months from the registration
• • Molecular confirmation of the diagnosis (WWTR1-CAMTA1 or YAP1-TFE3)
• • Adult patients (aged ≥ 18 years)